Rapamycin, a natural compound, has shown anti-aging and health benefits in various researches. Consequently, the popularity and demand for rapamycin supplements have surged significantly in the ...

But out of all the supplements and drugs he takes for 'living healthy forever', one key medicine that Bryan and other ...

In particular, the mechanistic target of rapamycin (mTOR) pathway has been tied to multiple age-related chronic disease processes, such as declining immune function, diminishing bone mineral ...

Inspired by a 2009 study that showed rapamycin could extend the lifespan of mice by up to 14%, along with a 2023 human trial where 65% of participants reported feeling healthier while on the drug ...

Charles Sawyers and colleagues have conducted a small early-stage clinical study to assess target modulation by the small-molecule inhibitor rapamycin. Rapamycin is approved to treat renal cancer ...

Rapamycin is an immunosuppressive agent with less-severe adverse effects than ciclosporin; Farkas et al., therefore, compared the efficacy of rapamycin and ciclosporin for the treatment of ...

The 47-year-old, who claims to be more than a decade younger biologically, took rapamycin for five years after lab studies showed it extended the lifespan of mice by 15 to 20 percent.

WAYNE, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and ...

Palvella Therapeutics has announced the issuance of a fifth patent for its lead product candidate, QTORIN™ rapamycin anhydrous gel, by the United States Patent and Trademark Office. This patent ...

The granted patent “Anhydrous Compositions of mTOR Inhibitors and Methods of Use” broadens protection for QTORIN rapamycin and the conditions related to its use in clinical indications ...